New data show that patients have higher overall treatment satisfaction with one daily injection of Victoza (liraglutide, 1.8mg dose) than they do with two daily injections of exenatide (10μg dose).
The data from the LEAD6 trial was recently presented at the 20th World Diabetes Congress (International Diabetes Federation).
Specifically, among the 379 patients who completed the Diabetes Treatment Satisfaction Questionnaires (DTSQ) during the trial, those taking once-daily Victoza perceived less hypoglycaemia (abnormally low blood sugar levels) or hyperglycaemia (abnormally high blood sugar levels) compared to those on twice-daily exenatide.
“The study shows Victoza is associated with higher patient satisfaction compared to exenatide,” said Professor Bain, Chair in Medicine (Diabetes) at Swansea University and Diabetes Lead Clinician for the ABM University Health Board.
“It is important to consider patient-reported outcomes data, because if a patient is satisfied with his or her treatment they are more likely to comply with the treatment over the long term, which is necessary in type 2 diabetes management,” he added.
Treatment satisfaction was also evaluated in patients who were either switched from twice-daily exenatide to once-daily Victoza or continued on once-daily Victoza for another 14 weeks. In these cases, switched patients had improved satisfaction compared to those who continued on Victoza from weeks 26-40.